Fierce Biotech Interviews Adam Farlow on The Top Line Podcast

In a recent episode of The Top Line podcast “What can we learn from 2024’s biotech IPOs?”, Fierce Biotech spoke with Adam Farlow, Global Chair of Baker McKenzie’s Capital Markets Practice Group, to explore the resurgence of the biotech IPO market.

The conversation highlighted the renewed momentum seen late this summer and delved into whether this uptick signifies a lasting market enthusiasm or merely a temporary rebound.

Adam shared valuable insight into the factors driving this trend, what the current market dynamic could mean for future biotech investments and his outlook for the biotech sector as we approach 2025. 

For more details, listen to the full podcast episode.